Clinical Trials Sponsored by PellePharm, Inc.

Total 35607 results

PellePharm, Inc.

Completed

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Basal Cell Nevus Syndrome

United States, Spain, Germany, United Kingdom, Italy, France, Belgium, Canada, Denmark, Netherlands
PellePharm, Inc.

Completed

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Basal Cell Nevus Syndrome

United Kingdom
PellePharm, Inc.

Completed

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (BCC)

Basal Cell Carcinomas

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
IGC Pharma LLC

Recruiting

IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's (IGC-AD1-P2)

Aggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive Outburst

United States, Canada, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Recruiting

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Completed

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Hodgkin Lymphoma, Adult

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Terminated

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids (NRR)

Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
Novan, Inc.
Synteract, Inc.; Therapeutics, Inc.

Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

Molluscum Contagiosum

United States
Vitality in Aging Research Group, Inc.

Withdrawn

VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

Aging
In-Home Addiction Treatment Institute, Inc.

Suspended

Effects of In-Home Addiction Treatment for First Responders

Substance Use Disorders

United States
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc; Immune-Onc Therapeutics; NiKang Therapeutics...

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Mylan Technologies Inc.
Mylan Inc.

Active, not recruiting

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Contraception

United States, Canada, Puerto Rico
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
SerenaGroup, Inc.
DrySee, Inc

Completed

A Comparison Between Two Post-operative Dressings (DrySee)

Surgical Incision

United States
Eisai Inc.
Quintiles, Inc.

Completed

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Non-Small Cell Lung Cancer

Belgium, Korea, Republic of, Italy, United States, Hungary, United Kingdom, Czechia
Athersys, Inc
Medpace, Inc.

Completed

Study to Examine the Effects of MultiStem in Ischemic Stroke

Ischemic Stroke

United States, United Kingdom
Seagen Inc.
Genentech, Inc.

Completed

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Sequella, Inc.
Quintiles, Inc.

Completed

Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

Tuberculosis

United States
Zogenix, Inc.
Synteract, Inc.

Completed

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Migraine

United States
University in Zielona Góra
ConvaTec Inc.

Unknown

Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction

Breast Cancer | Breast Reconstruction

Poland
OBELAB, Inc.
Helptrial Inc.

Not yet recruiting

Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.

Acute Ischemic Stroke Patients

Korea, Republic of
Athersys, Inc
Medpace, Inc.

Recruiting

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Ischemic Stroke

United States, Taiwan
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
ModernaTX, Inc.
Aetion, Inc.

Active, not recruiting

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

SARS-CoV-2

United States
Eisai Inc.
Quintiles, Inc.

Terminated

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Australia, Russian Federation, India, Ukraine
AxeroVision, Inc.
ORA, Inc.

Completed

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Dry Eye

United States
Versartis Inc.

Completed

Long-Acting Growth Hormone in Children Compared to Daily rhGH (VELOCITY)

Growth Disorders
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Molluscum Contagiosum

United States
EmitBio Inc.

Completed

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

COVID19

United States
Xoft, Inc.
Icad, Inc.

Withdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Ductal Carcinoma In Situ | Invasive Ductal Carcinoma
Versartis Inc.

Completed

Versartis Trial in Children to Assess Long-Acting Growth Hormone (VERTICAL)

Pediatric Growth Hormone Deficiency

United States
EmitBio Inc.

Completed

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

COVID19

United States
Mylan Inc.

Completed

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Cystic Fibrosis

United States
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Healios Inc.
Genentech, Inc.

Completed

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

Multiple Sclerosis

United States
Evofem Inc.
Neothetics, Inc

Completed

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Central Abdominal Bulging

United States
Eisai Inc.
Quintiles, Inc.

Terminated

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Advanced or Metastatic Solid Tumors | Previously Untreated Gastric Cancer

United States, Russian Federation, United Kingdom, Ukraine
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

United States
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Multiple Myeloma

United States

3

Subscribe